Table 2.
Concomitant diagnoses and medications at 2006 and during follow-up
| DISH N = 45 (%) |
Control N = 47 (%) |
P value | ||
|---|---|---|---|---|
| Dyslipidemia | 2006 N (%) | (48.9) 22 | (29.8) 14 | 0.06 |
| 2016 N (%) | (81.1) 36 | (69.6) 32 | 0.176 | |
| HTN | 2006 N (%) | (62.2) 28 | (38.3) 18 | 0.02 |
| 2016 N (%) | (86.7) 39 | (59.6) 28 | 0.003 | |
| Type 2 DM | 2006 N (%) | (33.3) 15 | (8.5) 4 | 0.003 |
| 2016 N (%) | (59.1) 26 | (17) 8 | < 0.0001 | |
| Heart failure (HFrEF + HFpEF) | 2006 N (%) | 0 (0) | 0 (0) | |
| 2016 N (%) | 13 (28.9) | 12 (25.5) | 0.717 | |
| Aspirin treatment | 2006 N (%) | (35.6) 16 | (19.2) 9 | 0.077 |
| 2016 N (%) | (60) 27 | (44.7) 21 | 0.598 | |
| ACEi/ARB treatment | 2006 N (%) | (31.1) 14 | (14.9) 7 | 0.063 |
| 2016 N (%) | (62.2) 28 | (27.7) 13 | 0.0009 | |
| HMG-CoA reductase inhibitor treatment | 2006 N (%) | (40) 18 | (25.5) 12 | 0.138 |
| 2016 N (%) | (75) 33 | (51.1) 24 | 0.0185 | |
| Metformin treatment | 2006 N (%) | 10 (22.2) | 3 (6.4) | 0.029 |
| 2016 N (%) | 12 (26.7) | 4 (8.5) | 0.021 |
HFrEF heart failure with reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, ACEi/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker